Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2015

01.04.2015 | Meta-Analysis

Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

verfasst von: Feng Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji, Siyan Zhan

Erschienen in: Endocrine | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed. The study aimed to systematically evaluate the effect of GLP-1RAs on waist circumference in patients with type 2 diabetes. MEDLINE, EMBASE, the Cochrane library and www.​clinicaltrialgov​ were searched through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration ≥8 weeks. Weighted mean difference was estimated using random-effect model. Network meta-analysis was performed to supplement direct comparisons. Seventeen trials with 12 treatments were included. Overall, significant reductions on waist circumference following treatment of liraglutide—1.8 mg once daily (−5.24 cm, 95 % CI −7.68, −2.93), liraglutide—1.2 mg once daily (−4.73 cm, 95 % CI −6.68, −2.65) and exenatide—10 μg twice daily (−1.34 cm, 95 % CI −2.00, −0.75) were detected versus placebo. The reduction effect was more evident when compared with insulin and thiazolidinediones (range −1.71 to −8.03 cm). Compared with exenatide, liraglutide—0.6 mg once daily, taspoglutide, liraglutide—1.2 mg once daily and liraglutide—1.8 mg once daily significantly decreased waist circumference from −3.32 to −6.01 cm. Besides, liraglutide—1.8 mg once daily significantly decreased waist circumference by −1.73 cm (95 % CI −3.04, −0.55) versus sitagliptin, whereas no significant difference following liraglutide—1.2-mg-once-daily treatment was detected compared with liraglutide—1.8 mg once daily and sitagliptin. Reduction was observed with statistical significance for exenatide—10 μg twice daily compared with exenatide—5 μg twice daily (−1.21 cm, 95 % CI −2.43, −0.06). Ranking probability analysis indicated liraglutide—1.8 mg once daily and liraglutide—1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82 %, respectively. Some GLP-1RAs, especially liraglutide—1.8 mg once daily and liraglutide—1.2 mg once daily, were associated with a significant reduction in waist circumference.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
K.B. Hansen, F.K. Knop, J.J. Holst, T. Vilsbøll, Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int. J. Clin. Pract. 63, 1154–1160 (2009)CrossRefPubMed
2.
S. Goykhman, A. Drincic, J.C. Desmangles, M. Rendell, Insulin Glargine: A review 8 years after its introduction. Expert Opin. Pharmacother. 10, 705–718 (2009)CrossRefPubMed
3.
M.A. Nauck, M.M. Heimesaat, K. Behle, J.J. Holst, M.S. Nauck, R. Ritzel, M. Hüfner, W.H. Schmiegel, Effects of glucagon-like peptide 1 on counter regulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87, 1239–1246 (2002)CrossRefPubMed
4.
T. Vilsbøll, T. Krarup, S. Madsbad, J.J. Holst, Both GLP-l and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114, 115–121 (2003)CrossRefPubMed
5.
M. Zander, S. Madsbad, J.L. Madsen, J.J. Holst, Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 359, 824–830 (2002)CrossRefPubMed
6.
E. Wajcberg, A. Tavaria, Exenaride: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin. Pharmacother. 10, 135–142 (2009)CrossRefPubMed
7.
J.J. Neumiller, R.K. Campbell, Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 43, 1433–1444 (2009)CrossRefPubMed
8.
C.E. Ezenwaka, O. Okoye, C. Esonwune, P. Onuoha, C. Dioka, C. Osuji, C. Oguejiofor, S. Meludu, High Prevalence of Abdominal Obesity Increases the Risk of the Metabolic Syndrome in Nigerian Type 2 Diabetes Patients: Using the International Diabetes Federation Worldwide Definition. Metab. Syndr. Relat. Disord. 12, 277–282 (2014)CrossRefPubMed
9.
R. Bhushan, K.E. Elkind-Hirsch, M. Bhushan, W.J. Butler, K. Duncan, O. Marrioneaux, Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol. Ther. 11, 353–359 (2009)CrossRefPubMed
10.
J.A. Beckman, M.A. Creager, P. Libby, Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570–2581 (2002)CrossRefPubMed
11.
H.M. Lakka, D.E. Laaksonen, T.T. Lakka, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709–2716 (2002)CrossRefPubMed
12.
P.W. Wilson, R.B. D’Agostino, H. Parise, L. Sullivan, J.B. Meigs, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066–3072 (2005)CrossRefPubMed
13.
H. Nagao, S. Kashine, H. Nishizawa, T. Okada, T. Kimura, A. Hirata, S. Fukuda, J. Kozawa, N. Maeda, T. Kitamura, T. Yasuda, K. Okita, T. Hibuse, M. Tsugawa, A. Imagawa, T. Funahashi, I. Shimomura, Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovasc. Diabetol. 12, 88 (2013)CrossRefPubMedCentralPubMed
14.
R.R. Wing, B. Marquez, Behavioral aspects of weight loss in type 2 diabetes. Curr. Diab. Rep. 8, 126–131 (2008)CrossRefPubMed
15.
G. Van Valkenhoef, G. Lu, B. de Brock, H. Hillege, A.E. Ades, J. Nicky, Welton Automating network meta-analysis. Res. Synth. Methods 3, 285–299 (2012)CrossRef
16.
A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, H.J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1–12 (1996)CrossRefPubMed
17.
R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986)CrossRefPubMed
18.
J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)CrossRefPubMed
19.
G. Lu, A.E. Ades, Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105–3124 (2004)CrossRefPubMed
20.
G. Salanti, A.E. Ades, J.P. Ioannidis, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64, 163–171 (2011)CrossRefPubMed
21.
Spiegelhalter D.J., Best N.G., Carlin B.P., Van Der Linde A.: Bayesian measures of model complexity an fit. J. Royal. Stat. Soci.: Series B (Statistical Methodology) 64, 583–639 (2002)
22.
F. Song, D.G. Altman, A.M. Glenny, J.J. Deeks, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326, 472 (2003)CrossRefPubMedCentralPubMed
23.
Apovian C.M., Bergenstal R.M., Cuddihy R.M., Qu Y., Lenox S., Lewis M.S., Glass L.C.: Effects of exenatide combined with lifestyle modification in patients with type 2 Diabetes. Am. J. Med. 123, 468.e9–e17 (2010)
24.
J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, A.Y. Kwan, B.J. Hoogwerf, J. Rosenstock, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154, 103–112 (2011)CrossRefPubMed
25.
M. Diamant, L. Van Gaal, S. Stranks, B. Guerci, L. MacConell, H. Haber, J. Scism-Bacon, M. Trautmann, Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 35, 683–689 (2012)CrossRefPubMedCentralPubMed
26.
M. Davies, S. Heller, S. Sreenan, H. Sapin, O. Adetunji, A. Tahbaz, J. Vora, Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 36, 1368–1376 (2013)CrossRefPubMedCentralPubMed
27.
M.J. Davies, R. Donnelly, A.H. Barnett, S. Jones, C. Nicolay, A. Kilcoyne, Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes. Metab. 11, 1153–1162 (2009)CrossRefPubMedCentralPubMed
28.
R.A. DeFronzo, C. Triplitt, Y. Qu, M.S. Lewis, D. Maggs, L.C. Glass, Effects of exenatide plus rosiglitazone on (beta)-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 33, 951–957 (2010)CrossRefPubMedCentralPubMed
29.
G. Derosa, I.G. Franzetti, F. Querci, A. Carbone, L. Ciccarelli, M.N. Piccinni, E. Fogari, P. Maffioli, Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. Pharmacotherapy 33, 817–826 (2013)CrossRefPubMed
30.
T. Forst, G. Michelson, F. Ratter, M.M. Weber, S. Anders, M. Mitry, B. Wilhelm, A. Pfützner, Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet. Med. 29, 1115–1118 (2012)CrossRefPubMed
31.
H. Harder, L. Nielsen, D.T. Tu, A. Astrup, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27, 1915–1921 (2004)CrossRefPubMed
32.
T. Kadowaki, M. Namba, T. Imaoka, A. Yamamura, W. Goto, M.K. Boardman, H. Sowa, Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J. Diabetes Invest. 2, 210–217 (2011)CrossRef
33.
C.J. Li, J. Li, Q.M. Zhang, L. Lv, R. Chen, C.F. Lv, P. Yu, D.M. Yu, Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc. Diabetol. 11, 142 (2012)CrossRefPubMedCentralPubMed
34.
J. Liutkus, Rosas Guzman J., Norwood P., Pop L., Northrup J., Cao D., Trautmann M.: A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes. Obes. Metab. 12, 1058–1065 (2010)CrossRef
35.
R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, S. Filetti, A. Garber, A.B. Thomsen, H. Hartvig, M. Davies, 1860-LIRA-DPP-4 Study Group: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial. Int. J. Clin. Pract. 65, 397–407 (2011)CrossRefPubMedCentralPubMed
36.
I. Raz, V. Fonseca, M. Kipnes, L. Durrwell, J. Hoekstra, M. Boldrin, R. Balena, Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care 35, 485–487 (2012)CrossRefPubMedCentralPubMed
37.
R.R. Henry, S. Mudaliar, L. Kanitra, M. Woloschak, R. Balena, T-Emerge 3 Study Group: Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-emerge 3 trial. J. Clin. Endocrinol. Metab. 97, 2370–2379 (2012)CrossRefPubMed
38.
R.E. Pratley, D. Urosevic, M. Boldrin, R. Balena, T-emerge 6 Study Group: Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: A randomized, double-blind study (T-emerge 6). Diabetes Obes. Metab. 15, 234–240 (2013)CrossRefPubMed
39.
P. Hollander, B. Lasko, A.H. Barnett, M. Bengus, L. Kanitra, F.X. Pi-Sunyer, R. Balena, Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) 21, 238–247 (2013)CrossRef
40.
D. Mundil, A. Cameron-Vendrig, M. Husain, GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab. Vasc. Dis. Res. 9, 95–108 (2012)CrossRefPubMed
41.
D. Lorber, GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc. Ther. 31, 238–249 (2013)CrossRefPubMed
42.
M. Buysschaert, V. Preumont, P.R. Oriot, I. Paris, M. Ponchon, D. Scarnière, P. Selvais, UCL Study Group for Exenatide: One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 36, 381–388 (2010)CrossRefPubMed
43.
M.C. Bunck, M. Diamant, B. Eliasson, A. Cornér, R.M. Shaginian, R.J. Heine, M.R. Taskinen, H. Yki-Järvinen, U. Smith, Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33, 1734–1737 (2010)CrossRefPubMedCentralPubMed
44.
Y. Matsuzawa, T. Funahashi, T. Nakamura, The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler. Thromb. 18, 629–639 (2011)CrossRefPubMed
45.
H. Yanai, H. Adachi, H. Hamasaki, Y. Masui, R. Yoshikawa, S. Moriyama, S. Mishima, A. Sako, Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J. Clin. Med. Res. 4, 251–258 (2012)PubMedCentralPubMed
46.
S. Brunton, GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int. J. Clin. Pract. 68, 557–567 (2014)CrossRefPubMedCentralPubMed
47.
J. Jendle, M.A. Nauck, D.R. Matthews, A. Frid, K. Hermansen, M. Düring, M. Zdravkovic, B.J. Strauss, A.J. Garber, LEAD-2 and LEAD-3 Study Groups: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab. 11, 1163–1172 (2009)CrossRefPubMed
48.
L. van Bloemendaal, J.S. Ten Kulve, S.E. la Fleur, R.G. Ijzerman, M. Diamant, Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J. Endocrinol. 221, T1–T16 (2014)CrossRefPubMed
49.
Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, N.H. Greig, GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106, 1285–1290 (2009)CrossRefPubMedCentralPubMed
50.
P.L. McClean, V. Parthsarathy, E. Faivre, C. Holscher, The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci. 31, 6587–6594 (2011)CrossRefPubMed
51.
D.M. Caldwell, A.E. Ades, J.P. Higgins, Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331, 897–900 (2005)CrossRefPubMedCentralPubMed
Metadaten
Titel
Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis
verfasst von
Feng Sun
Shanshan Wu
Shuxia Guo
Kai Yu
Zhirong Yang
Lishi Li
Yuan Zhang
Linong Ji
Siyan Zhan
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0373-0

Weitere Artikel der Ausgabe 3/2015

Endocrine 3/2015 Zur Ausgabe

Editorial

PSP/reg: a potent and enigmatic trophic factor, which is upregulated during the pathogenesis of diabetes

Original Article

Acute effects of acylated ghrelin on salbutamol-induced metabolic actions in humans

Original Article

The Langerhans islet cells of female rabbits are differentially affected by hypothyroidism depending on the islet size

Original Article

Effects of restoration of the euthyroid state on epicardial adipose tissue and carotid intima media thickness in subclinical hypothyroid patients

Endocrine Genetics/Epigenetics

The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) gene in relation to obesity and metabolic phenotypes in a Taiwanese population

Original Article

Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise